CPA
MRNA icon

Compass Planning Associates’s Moderna MRNA Stock Holding History

Compass Planning Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-900
Closed -$24.8K – 87
2025
Q2 		$24.8K Hold
900
– – 0.02% 76
2025
Q1 		$25.5K Hold
900
– – 0.03% 76
2024
Q4 		$37.4K Buy
+900
New +$43K 0.04% 65

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Compass Planning Associates's MRNA Position: Q3 2025 in Review

Compass Planning Associates sold out of Moderna (MRNA) in Q3 2025, closing a stake of 900 shares — an estimated $24.8K sold.

Compass Planning Associates first reported a position in MRNA in Q4 2024 and held it in 3 quarters. The position peaked at $37.4K in Q4 2024. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Compass Planning Associates reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • Compass Planning Associates sold 900 Moderna shares in Q3 2025, an estimated $24.8K.
  • Compass Planning Associates first reported a position in Moderna in Q4 2024 and held it in 3 quarters.
  • Compass Planning Associates's Moderna position peaked at $37.4K in Q4 2024.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Compass Planning Associates's 13F filing for Q3 2025, filed 22 Oct 2025.